Ultragenyx Pharmaceutical Inc (RARE) Inventory Turnover Ratio, from first quarter 2026 to first quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Ultragenyx Pharmaceutical Inc   (NASDAQ: RARE)
 

Ultragenyx Pharmaceutical Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the first quarter 2026, Ultragenyx Pharmaceutical Inc 's inventory turnover ratio sequentially decreased to 2.15 in the first quarter 2026, otherwise the ratio remained above the average, as RARE's markets remain strong.Ultragenyx Pharmaceutical Inc 's average inventory processing period in the Mar 31 2026 quarter, has increased to 170 days, from 164 days, in the Dec 31 2025 quarter.

Within Healthcare sector 186 other companies have achieved higher inventory turnover ratio. While Inventory turnover ratio total ranking has improved so far during the I Quarter 2026, to 1066, from total ranking in the fourth quarter 2025 at 1136.

RARE Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Ultragenyx Pharmaceutical Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RARE Inventory Turnover Ratio (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Inventory Growth 19.48 % 15.54 % 20.46 % 15.85 % 28.2 %
Y / Y Cost of Sales Growth 4.67 % 73.7 % 33.16 % 8.09 % 63.47 %
Inventory Turnover Ratio (TTM) 2.15 2.22 2.04 1.98 2.01
RARE's Total Ranking # 1066 # 1136 # 673 # 934 # 721
Average inventory processing period 170 165 179 184 181
Seq. Inventory Growth 5.77 % -0.38 % 12.26 % 1.01 % 2.28 %
Seq. Cost of Sales Growth 2.23 % 4.84 % 21.69 % -19.75 % 69.66 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 50
Healthcare Sector # 187
Overall Market # 1066

Inventory Turnover Ratio Statistics
High Average Low
2.22 1.22 0.2
(Dec 31 2025)   (Mar 31 2019)



RARE Company Profile >> Back to RARE Efficiency Comparisons >> Compare RARE Inventory Turnover Ratio to its Competitors

Financial Statements
Ultragenyx Pharmaceutical Inc 's Inventories $ 55 Millions Visit RARE's Balance sheet
Ultragenyx Pharmaceutical Inc 's Cost of Revenues TTM $ 110 Millions Visit RARE's Income Statement
What are RARE's Sales? Visit RARE's Sales by Segment

Other Inventory Turnover Ratios
Ultragenyx Pharmaceutical Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
RARE's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for RARE's Competitors
Inventory Turnover Ratio for RARE's Suppliers
Inventory Turnover Ratio for RARE's Customers

You may also want to know
RARE's Sales Growth Rates RARE's Pe Price to earnings ratio RARE's Receivables Turnover Ratio RARE's Stock Quote
RARE's Net Income Growth Rates RARE's Ps Price to Sales ratio RARE's Sales per Employee RARE's Asset Turnover Ratio
RARE's Net Margin RARE's Pb Price to Book ratio RARE's Financial Strength Ratios RARE's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Mar 31 2026 Inventories at quarter ending Mar 31 2026
Steris Plc  5.27 $ 3,309.400  Millions$ 628  Millions
Bristol myers Squibb Company  5.24 $ 14,324.000  Millions$ 2,735  Millions
Harrow Inc   5.11 $ 69.568  Millions$ 14  Millions
Integer Holdings Corporation  5.11 $ 1,365.000  Millions$ 267  Millions
Tactile Systems Technology Inc   5.08 $ 81.000  Millions$ 16  Millions
Integrated Biopharma Inc  4.96 $ 45.000  Millions$ 9  Millions
Ufp Technologies Inc   4.95 $ 436.000  Millions$ 88  Millions
Polomar Health Services, Inc.  4.79 $ 0.642  Millions$ 0  Millions
Henry Schein Inc   4.70 $ 9,209.000  Millions$ 1,959  Millions
Bionexus Gene Lab Corp   4.70 $ 4.191  Millions$ 1  Millions
Medinotec Inc   4.69 $ 4.864  Millions$ 1  Millions
West Pharmaceutical Services Inc   4.68 $ 2,052.000  Millions$ 439  Millions
Scilex Holding Company  4.48 $ 14.462  Millions$ 3  Millions
Guardant Health Inc   4.41 $ 379.203  Millions$ 86  Millions
Idexx Laboratories Inc  4.38 $ 1,690.942  Millions$ 386  Millions
Envista Holdings Corporation  4.36 $ 1,267.000  Millions$ 290  Millions
Inotiv Inc   4.25 $ 175.895  Millions$ 41  Millions
Cryoport inc   4.23 $ 96.609  Millions$ 23  Millions
Teva Pharmaceutical Industries Limited  4.22 $ 8,317.000  Millions$ 1,971  Millions
Incyte Corporation  4.21 $ 403.465  Millions$ 96  Millions
Electromed Inc   4.16 $ 14.195  Millions$ 3  Millions
Vericel Corporation  4.15 $ 73.494  Millions$ 18  Millions
Sharps Technology Inc   4.12 $ 3.585  Millions$ 1  Millions
Coherus Oncology inc   4.11 $ 14.975  Millions$ 4  Millions
Novocure Limited  4.08 $ 167.287  Millions$ 41  Millions
Lifeward ltd   4.08 $ 13.275  Millions$ 3  Millions
Ge Healthcare Technologies Inc   4.04 $ 9,262.000  Millions$ 2,294  Millions
Koru Medical Systems Inc   3.99 $ 16.468  Millions$ 4  Millions
3m Company  3.94 $ 15,087.000  Millions$ 3,830  Millions
Iridex Corp  3.92 $ 32.247  Millions$ 8  Millions

Date modified: 2026-08-30T14:42:55+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.